Telix Pharmaceuticals (TLX) Shares Outstanding (Weighted Average) (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Shares Outstanding (Weighted Average) for 3 consecutive years, with $480.0 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 119.27% to $480.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $480.0 million through Dec 2025, up 119.27% year-over-year, with the annual reading at $480.0 million for FY2025, 15.93% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $480.0 million at Telix Pharmaceuticals, up from $218.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $480.0 million in Q4 2025, with the low at $210.7 million in Q4 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $303.2 million, with a median of $218.9 million recorded in 2024.
  • The sharpest move saw Shares Outstanding (Weighted Average) rose 3.87% in 2024, then surged 119.27% in 2025.
  • Over 3 years, Shares Outstanding (Weighted Average) stood at $210.7 million in 2023, then rose by 3.87% to $218.9 million in 2024, then skyrocketed by 119.27% to $480.0 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $480.0 million, $218.9 million, and $210.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.